Entry Point Capital, LLC Anavex Life Sciences Corp. Transaction History
Entry Point Capital, LLC
- $112 Billion
- Q1 2024
A detailed history of Entry Point Capital, LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Entry Point Capital, LLC holds 20,007 shares of AVXL stock, worth $82,428. This represents 0.09% of its overall portfolio holdings.
Number of Shares
20,007
Previous 4,247
371.09%
Holding current value
$82,428
Previous $39.5 Million
157.55%
% of portfolio
0.09%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding AVXL
# of Institutions
159Shares Held
31.6MCall Options Held
910KPut Options Held
1.35M-
State Street Corp Boston, MA7.3MShares$30.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$27.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.41MShares$18.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.71MShares$7.06 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC851KShares$3.51 Million0.0% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $321M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...